Lemtrada 12mg Infusion

Product Description

1. Technical Specifications

---

2. Product Description

Lemtrada (Alemtuzumab) is a humanized monoclonal antibody directed against the CD52 antigen present on the surface of T and B lymphocytes.
It causes depletion of these immune cells, leading to immune system rebalancing, which reduces inflammation and prevents relapses in autoimmune disease.

It is primarily indicated for the treatment of Relapsing forms of Multiple Sclerosis (MS) in adults.

---

3. Product Highlights

• Course 1: 12 mg/day for 5 consecutive days (total 60 mg)

• Course 2: 12 mg/day for 3 consecutive days (total 36 mg), 12 months after first course
  Storage Conditions | Store at 28 C (refrigerated); do not freeze; protect from light

---

4. Therapeutic Uses

• Relapsing-Remitting Multiple Sclerosis (RRMS)

  • Reduces relapse rate

  • Slows progression of disability

  • Shown effective in patients who have failed 1 disease-modifying therapy

---

5. Side Effects

Common:

• Rash, pruritus

• Headache, fever, fatigue

• Nausea, diarrhea

• Infections (respiratory, urinary tract, herpes reactivation)

• Infusion-related reactions (flushing, chills, hypotension)

Serious / Severe:

• Autoimmune conditions: thyroid disorders, idiopathic thrombocytopenic purpura (ITP), nephropathies

• Serious infections (opportunistic, hepatitis, TB reactivation, herpes, fungal infections)

• Malignancy risk: thyroid cancer, melanoma, lymphoproliferative disorders

• Cytopenias: prolonged lymphopenia, anemia, neutropenia

• Infusion-related anaphylaxis (rare but life-threatening)

---

6. Precautions

• Premedication: Corticosteroids, antihistamines, antipyretics before infusion to reduce infusion reactions.

• Infection Risk: Screen for hepatitis, TB, HIV before therapy; prophylactic antivirals recommended for herpes prevention.

• Autoimmunity Monitoring: Regular thyroid function, CBC, renal function, urinalysis for 4 years after last dose.

• Cancer Risk: Long-term monitoring for malignancies.

• Pregnancy & Breastfeeding: Contraindicated (teratogenic and immunosuppressive effects).

• Vaccination: Avoid live vaccines during and for several months after treatment.

• Hospital/Clinic Setting: Must be administered under supervision with emergency resuscitation support available.

Comprehensive Treatment Option

Lemtrada 12mg Infusion offers a robust therapeutic choice, especially favored by healthcare providers for managing specific medical conditions in adults. With a precise dosage format and convenient liquid injection, it is tailored to meet high efficacy standards. The product is accessible in India through reliable distribution networks including traders and wholesalers.


Proper Storage and Handling

To retain its therapeutic potency, Lemtrada 12mg Infusion should always be stored in a cool and dry environment. Vendors and healthcare professionals must carefully adhere to these instructions to guarantee optimal storage conditions and safeguard product quality from manufacturer to patient.